KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population |
| |
| Authors: | Andrzej Wiśniewski Renata Jankowska Ewa Passowicz-Muszyńska Elżbieta Wiśniewska Edyta Majorczyk Izabela Nowak Irena Frydecka Piotr Kuśnierczyk |
| |
| Affiliation: | 1. Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc?aw, Poland;2. Department of Pulmonology and Lung Cancer, Silesian Piasts University of Medicine, Wroc?aw, Poland;3. Chair of Biochemistry and Physiology, Institute of Physiotherapy, Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland;4. Laboratory of Immunopathology, Department of Experimental Therapy, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc?aw, Poland;5. Department of Hematology, Neoplastic Diseases and Bone Marrow Transplantation, Medical University, Wroc?aw, Poland;6. Research and Development Centre, Regional Specialist Hospital in Wroc?aw, Poland |
| |
| Abstract: | ![]()
Non-small cell lung carcinoma (NSCLC) is a multifactorial disease influenced by both environmental and genetic factors. Here, we examined whether the repertoire of genes encoding killer immunoglobulin-like receptors (KIR) and genes for their ligands, C1/C2 and Bw4, may affect a susceptibility to NSCLC and response to treatment. We typed 269 NSCLC patients and 690 healthy control individuals for KIR genes and for their ligands. KIR genes were not associated with NSCLC. C1C2 genotype was less frequent whereas both C1C1 and C2C2 homozygotes were more frequent in patients than in controls (χ(2)=7.73; df=2; p=0.021). Patients positive for KIR2DL2 and KIR2DS2 gene and homozygous for the C1 ligand were 6 times more likely to respond to treatment than those with other genotypes (p=0.034). In accordance with this, patients with the KIR2DL2+/KIR2DS2+, C1C1 genotype survived longer than others (p=0.0094). Median survival was 23months for KIR2DL2/2DS2/C1C1-positive patients, but only 10months for those with other genotypes. |
| |
| Keywords: | HLA-I, human leukocyte antigen class I KIR, killer cell immunoglobulin-like receptor NK, natural killer NSCLC, non-small cell lung cancer |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
